First early benefit assessment: G-BA follows up

15.12.2011 18:11

The first early benefit assessment in Germany was completed today by a resolution of the Federal Joint Committee (G-BA) on ticagrelor (Brilique).

vfa General Manager Birgit Fischer explains: “The G-BA, as master of the process, has completed the first early benefit assessment in Germany. In its decision on ticagrelor, it partly followed the assessment of the Institute for Quality and Efficiency in Health Care (IQWiG), but not the IQWiG methodology for classifying the additional benefit. This shows that, in principle, there are still considerable uncertainties that need to be clarified for future proceedings. Because today it turned out that there are different methodological approaches that are practiced side by side. In the interests of patients, there must be methodological clarity. They, like the pharmaceutical companies involved, need the certainty that the early benefit assessment is based on established methodological standards. Ultimately, from the patient’s perspective, reimbursement decisions are decisions about who gets something and who doesn’t.”